Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod

Evaluation of the automated LIAISON® SARS-CoV-2 TrimericS IgG assay for the detection of circulating antibodies

(2021) Fabrizio Bonelli et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

WHO International Standard for anti-SARS-CoV-2 immunoglobulin

(2021) Paul A Kristiansen et al.   LANCET

Immunosenescence in multiple sclerosis: the identification of new therapeutic targets

(2021) María Dema et al.   AUTOIMMUNITY REVIEWS

Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab

(2021) Antonio Gallo et al.   NEUROLOGICAL SCIENCES

Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients

(2021) Nassim Kamar et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association of Disease-Modifying Treatment and Anti-CD20 Infusion Timing With Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With Multiple Sclerosis

(2021) Giulio Disanto et al.   JAMA Neurology

Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab

(2021) Livnat Brill et al.   JAMA Neurology

Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study

(2021) Anat Achiron et al.   JOURNAL OF NEUROIMMUNOLOGY

Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study

(2020) Amit Bar-Or et al.   NEUROLOGY

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

(2020) Lindsey R. Baden et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis

(2015) L. Kappos et al.   NEUROLOGY